MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
2.930
+0.050
+1.74%
After Hours: 2.930 0 0.00% 19:59 01/02 EST
OPEN
2.830
PREV CLOSE
2.880
HIGH
2.960
LOW
2.820
VOLUME
107.43K
TURNOVER
--
52 WEEK HIGH
27.00
52 WEEK LOW
2.738
MARKET CAP
6.64M
P/E (TTM)
-0.0837
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PCSA last week (1222-1226)?
Weekly Report · 12/29/2025 09:48
Weekly Report: what happened at PCSA last week (1215-1219)?
Weekly Report · 12/22/2025 09:48
Processa Pharmaceuticals (PCSA) Price Target Increased by 2,400.00% to 25.50
NASDAQ · 12/21/2025 14:22
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20/2025 05:44
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
NASDAQ · 12/18/2025 14:21
Why MillerKnoll Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/18/2025 09:59
Here’s Why Penny Stock Processa Pharmaceuticals Stock (PCSA) Is Exploding Today
TipRanks · 12/17/2025 20:26
Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?
Benzinga · 12/17/2025 18:10
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.